Literature DB >> 12417571

Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy.

Georg M N Behrens1, Anne-Rose Boerner, Klaus Weber, Joerg van den Hoff, Johann Ockenga, Georg Brabant, Reinhold E Schmidt.   

Abstract

Insulin resistance is a frequently observed side effect of highly active antiretroviral therapy (HAART). Currently, very little is known about the mechanisms or specific tissues involved. We aimed to identify possible defects in skeletal muscle glucose uptake and metabolism in HIV patients receiving HAART. Whole-body glucose disposal and oxidation were determined by combination of the euglycemic-hyperinsulinemic clamp technique and indirect calorimetry. Muscle glucose uptake of the thighs was measured simultaneously by dynamic 2[(18)F]fluoro-2-deoxy-D-glucose positron emission tomography. Patients receiving HAART had signs of lipodystrophy as confirmed by dual energy x-ray absorptiometry. Whole-body glucose disposal was significantly reduced in these patients compared with untreated patients. Analysis of kinetic constants using a three-compartment model indicated reduced skeletal glucose uptake caused by significantly impaired glucose transport and phosphorylation. Skeletal muscle glucose uptake was reduced by 66% in treated patients and explained 46% and 43% of whole-body glucose disposal in patients on HAART and therapy-naive patients, respectively. Insulin-stimulated whole-body oxidative and nonoxidative glucose disposal was significantly lower in the treated group, as was suppressive insulin action on lipolysis. To our knowledge, this is the first report providing in vivo evidence that, in lipodystrophic HIV patients, impaired glucose transport and phosphorylation cause reduced insulin-mediated glucose uptake.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12417571      PMCID: PMC151608          DOI: 10.1172/JCI15626

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  44 in total

1.  Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells.

Authors:  X R Pan-Zhou; L Cui; X J Zhou; J P Sommadossi; V M Darley-Usmar
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

2.  Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and B-cell function in HIV-infected patients.

Authors:  M P Dubé; H Edmondson-Melançon; D Qian; R Aqeel; D Johnson; T A Buchanan
Journal:  J Acquir Immune Defic Syndr       Date:  2001-06-01       Impact factor: 3.731

3.  Insulin sensitivity of suppression of endogenous glucose production is the single most important determinant of glucose tolerance.

Authors:  P N Båvenholm; J Pigon; C G Ostenson; S Efendic
Journal:  Diabetes       Date:  2001-06       Impact factor: 9.461

4.  The HIV protease inhibitor indinavir decreases insulin- and contraction-stimulated glucose transport in skeletal muscle.

Authors:  L A Nolte; K E Yarasheski; K Kawanaka; J Fisher; N Le; J O Holloszy
Journal:  Diabetes       Date:  2001-06       Impact factor: 9.461

5.  The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance.

Authors:  M Caron; M Auclair; C Vigouroux; M Glorian; C Forest; J Capeau
Journal:  Diabetes       Date:  2001-06       Impact factor: 9.461

6.  The HIV protease inhibitor nelfinavir induces insulin resistance and increases basal lipolysis in 3T3-L1 adipocytes.

Authors:  A Rudich; S Vanounou; K Riesenberg; M Porat; A Tirosh; I Harman-Boehm; A S Greenberg; F Schlaeffer; N Bashan
Journal:  Diabetes       Date:  2001-06       Impact factor: 9.461

7.  Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.

Authors:  M van der Valk; E H Gisolf; P Reiss; F W Wit; A Japour; G J Weverling; S A Danner
Journal:  AIDS       Date:  2001-05-04       Impact factor: 4.177

8.  Metabolic effects of indinavir in healthy HIV-seronegative men.

Authors:  M A Noor; J C Lo; K Mulligan; J M Schwarz; R A Halvorsen; M Schambelan; C Grunfeld
Journal:  AIDS       Date:  2001-05-04       Impact factor: 4.177

9.  Kinetic modeling of [(18)F]FDG in skeletal muscle by PET: a four-compartment five-rate-constant model.

Authors:  A Bertoldo; P Peltoniemi; V Oikonen; J Knuuti; P Nuutila; C Cobelli
Journal:  Am J Physiol Endocrinol Metab       Date:  2001-09       Impact factor: 4.310

10.  Acyl-CoA inhibition of hexokinase in rat and human skeletal muscle is a potential mechanism of lipid-induced insulin resistance.

Authors:  A L Thompson; G J Cooney
Journal:  Diabetes       Date:  2000-11       Impact factor: 9.461

View more
  17 in total

Review 1.  [Adverse effects of antiretroviral therapy. Aspects of pathogenesis].

Authors:  U Seybold; R Draenert; F D Goebel
Journal:  Internist (Berl)       Date:  2003-06       Impact factor: 0.743

Review 2.  Cardiovascular implications of HIV-associated dyslipidemic lipodystrophy.

Authors:  Rajagopal V Sekhar; Farook Jahoor; Henry J Pownall; Christie M Ballantyne; Ashok Balasubramanyam
Journal:  Curr Atheroscler Rep       Date:  2004-05       Impact factor: 5.113

3.  Inappropriately low glycated hemoglobin values and hemolysis in HIV-infected patients.

Authors:  Marie-Emilienne Diop; Jean-Philippe Bastard; Natacha Meunier; Sandrine Thévenet; Mustapha Maachi; Jacqueline Capeau; Gilles Pialoux; Corinne Vigouroux
Journal:  AIDS Res Hum Retroviruses       Date:  2006-12       Impact factor: 2.205

4.  Intramyocellular lipid quantification: comparison between 3.0- and 1.5-T (1)H-MRS.

Authors:  Martin Torriani; Bijoy J Thomas; Miriam A Bredella; Hugue Ouellette
Journal:  Magn Reson Imaging       Date:  2007-01-18       Impact factor: 2.546

5.  Depot-specific regulation of glucose uptake and insulin sensitivity in HIV-lipodystrophy.

Authors:  C Hadigan; D Kamin; J Liebau; S Mazza; S Barrow; M Torriani; R Rubin; S Weise; A Fischman; S Grinspoon
Journal:  Am J Physiol Endocrinol Metab       Date:  2005-08-30       Impact factor: 4.310

Review 6.  Molecular mechanisms for insulin resistance in treated HIV-infection.

Authors:  Paul W Hruz
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2011-06       Impact factor: 4.690

Review 7.  Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management.

Authors:  Absalon D Gutierrez; Ashok Balasubramanyam
Journal:  Endocrine       Date:  2011-12-02       Impact factor: 3.633

8.  Effects of the human immunodeficiency virus-protease inhibitor, ritonavir, on basal and catecholamine-stimulated lipolysis.

Authors:  Diane C Adler-Wailes; Hanguan Liu; Faiyaz Ahmad; Ningping Feng; Constantine Londos; Vincent Manganiello; Jack A Yanovski
Journal:  J Clin Endocrinol Metab       Date:  2005-03-01       Impact factor: 5.958

Review 9.  Positron emission tomography in patients suffering from HIV-1 infection.

Authors:  Mike Sathekge; Ingeborg Goethals; Alex Maes; Christophe van de Wiele
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-04-07       Impact factor: 9.236

Review 10.  Metabolic complications associated with HIV protease inhibitor therapy.

Authors:  David Nolan
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.